EDISON EQUITY RESEARCH - TRIMEL PHARMACEUTICALS
2014年10月20日 - 10:02PM
InvestorsHub NewsWire
EDISON EQUITY RESEARCH:
TRIMEL PHARMACEUTICALS - TRT UNDER FDA
SPOTLIGHT
A joint panel of two FDA advisory committees voted in September to
modify the labelling of TRT products to curtail usage when clinical
benefit may not be definitive. While it is unclear how the FDA will
respond, we believe that end-user demand for TRT will largely
persist and that Natesto’s novel delivery should generate interest
when launched in H115.
Trimel is a Canadian specialty pharmaceutical company. Natesto and
Tefina deliver testosterone through a bio-adhesive nasal gel drug
delivery technology platform, for male hypogonadism and female
orgasmic disorder (FOD), respectively. Estrace is being marketed
for HRT in Canada.
To view our full report, please click here:
http://www.edisoninvestmentresearch.com/research/report/trimel-pharmaceuticals5
Click here to view all of Edison Investment
Research’s published reports
Trilogy International Pa... (TSX:TRL)
過去 株価チャート
から 5 2024 まで 6 2024
Trilogy International Pa... (TSX:TRL)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Trilogy International Partners Inc (トロント証券取引所): 0 recent articles
その他のTrimel Pharmaceuticals Corpニュース記事